167 related articles for article (PubMed ID: 35611229)
1. A Pilot Study for Return of Individual Pharmacogenomic Results to Population-Based Cohort Study Participants.
Ohneda K; Hiratsuka M; Kawame H; Nagami F; Suzuki Y; Suzuki K; Uruno A; Sakurai-Yageta M; Hamanaka Y; Taira M; Ogishima S; Kuriyama S; Hozawa A; Tomita H; Minegishi N; Sugawara J; Danjoh I; Nakamura T; Kobayashi T; Yamaguchi-Kabata Y; Tadaka S; Obara T; Hishimuma E; Mano N; Matsuura M; Sato Y; Nakasone M; Honkura Y; Suzuki J; Katori Y; Kakuta Y; Masamune A; Aoki Y; Nakayama M; Kure S; Kinoshita K; Fuse N; Yamamoto M
JMA J; 2022 Apr; 5(2):177-189. PubMed ID: 35611229
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
[TBL] [Abstract][Full Text] [Related]
3. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
[TBL] [Abstract][Full Text] [Related]
4. Description of Pharmacogenomic Testing Among Patients Admitted to the Intensive Care Unit After Cardiovascular Surgery.
Peterson PE; Nicholson WT; Moyer AM; Arendt CJ; Smischney NJ; Seelhammer TG; Krecke CA; Haney RM; Yaw EJ; Chlan LL
J Intensive Care Med; 2021 Nov; 36(11):1281-1285. PubMed ID: 32734840
[TBL] [Abstract][Full Text] [Related]
5. Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation.
Lau-Min KS; Varughese LA; Nelson MN; Cambareri C; Reddy NJ; Oyer RA; Teitelbaum UR; Tuteja S
BMC Cancer; 2022 Jan; 22(1):47. PubMed ID: 34996412
[TBL] [Abstract][Full Text] [Related]
6. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
7. Using Pharmacogenomic Testing in Primary Care: Protocol for a Pilot Randomized Controlled Study.
Manzor Mitrzyk B; Kadri R; Farris KB; Ellingrod VL; Klinkman MS; Ruffin Iv MT; Plegue MA; Buis LR
JMIR Res Protoc; 2019 Aug; 8(8):e13848. PubMed ID: 31429417
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic landscape of Indian population using whole genomes.
Sahana S; Bhoyar RC; Sivadas A; Jain A; Imran M; Rophina M; Senthivel V; Kumar Diwakar M; Sharma D; Mishra A; Sivasubbu S; Scaria V
Clin Transl Sci; 2022 Apr; 15(4):866-877. PubMed ID: 35338580
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial.
Grace C; Larriva MM; Steiner HE; Marupuru S; Campbell PJ; Patterson H; Cropp CD; Quinn D; Klimecki W; Nix DE; Warholak T; Karnes JH
Clin Transl Sci; 2021 Nov; 14(6):2532-2543. PubMed ID: 34431601
[TBL] [Abstract][Full Text] [Related]
10. Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology.
Shriver SP; Adams D; McKelvey BA; McCune JS; Miles D; Pratt VM; Ashcraft K; McLeod HL; Williams H; Fleury ME
J Clin Oncol; 2024 Apr; 42(10):1181-1192. PubMed ID: 38386947
[TBL] [Abstract][Full Text] [Related]
11. Attitudes toward pharmacogenetics in patients undergoing
Lee G; Varughese LA; Conway L; Stojinski C; Ashokkumar S; Monono K; Matthai W; Kolansky DM; Giri J; Tuteja S
Per Med; 2022 Mar; 19(2):93-101. PubMed ID: 34984913
[TBL] [Abstract][Full Text] [Related]
12. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
[TBL] [Abstract][Full Text] [Related]
13. Personal genome testing on physicians improves attitudes on pharmacogenomic approaches.
Lee KH; Min BJ; Kim JH
PLoS One; 2019; 14(3):e0213860. PubMed ID: 30921347
[TBL] [Abstract][Full Text] [Related]
14. Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study.
Tagwerker C; Carias-Marines MJ; Smith DJ
JMIRx Med; 2022 May; 3(2):e32902. PubMed ID: 37725552
[TBL] [Abstract][Full Text] [Related]
15. The Value of Pharmacogenomics for White and Indigenous Americans after Kidney Transplantation.
Brady A; Misra S; Abdelmalek M; Kekic A; Kunze K; Lim E; Jakob N; Mour G; Keddis MT
Pharmacy (Basel); 2023 Aug; 11(4):. PubMed ID: 37624080
[TBL] [Abstract][Full Text] [Related]
16. Development and Implementation of In-House Pharmacogenomic Testing Program at a Major Academic Health System.
Mroz P; Michel S; Allen JD; Meyer T; McGonagle EJ; Carpentier R; Vecchia A; Schlichte A; Bishop JR; Dunnenberger HM; Yohe S; Thyagarajan B; Jacobson PA; Johnson SG
Front Genet; 2021; 12():712602. PubMed ID: 34745204
[TBL] [Abstract][Full Text] [Related]
17. Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions.
Hoffecker G; Kanter GP; Xu Y; Matthai W; Kolansky DM; Giri J; Tuteja S
Per Med; 2022 Jan; 19(1):41-49. PubMed ID: 34881641
[TBL] [Abstract][Full Text] [Related]
18. Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population.
Lunenburg CATC; Hauser AS; Ishtiak-Ahmed K; Gasse C
Clin Transl Sci; 2020 Jul; 13(4):798-806. PubMed ID: 32166845
[TBL] [Abstract][Full Text] [Related]
19. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol.
Bielinski SJ; Olson JE; Pathak J; Weinshilboum RM; Wang L; Lyke KJ; Ryu E; Targonski PV; Van Norstrand MD; Hathcock MA; Takahashi PY; McCormick JB; Johnson KJ; Maschke KJ; Rohrer Vitek CR; Ellingson MS; Wieben ED; Farrugia G; Morrisette JA; Kruckeberg KJ; Bruflat JK; Peterson LM; Blommel JH; Skierka JM; Ferber MJ; Black JL; Baudhuin LM; Klee EW; Ross JL; Veldhuizen TL; Schultz CG; Caraballo PJ; Freimuth RR; Chute CG; Kullo IJ
Mayo Clin Proc; 2014 Jan; 89(1):25-33. PubMed ID: 24388019
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic (PGx) Counseling: Exploring Participant Questions about PGx Test Results.
Schmidlen T; Sturm AC; Scheinfeldt LB
J Pers Med; 2020 Apr; 10(2):. PubMed ID: 32340147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
